Olympus Corporation of the Americas has announced the U.S. launch of SecureFlex™, its newest single-use fine needle biopsy (FNB) device designed for endoscopic ultrasound–guided tissue sampling, particularly in challenging anatomies such as the pancreatic head and uncinate process. The SecureFlex FNB needle is engineered to collect larger, intact tissue samples, addressing growing diagnostic needs in pancreatic cancer as molecular profiling and targeted therapies increasingly depend on high-quality histologic specimens. It is available in 19G, 22G, and 25G sizes. Key design features include a dual-beveled cutting tip to preserve tissue architecture, nitinol construction to maintain needle integrity in tortuous anatomy, and…
Author: Abhay Panchal
The American Gastroenterological Association has announced the AGA Tech Summit 2026, a flagship gathering designed to connect gastroenterologists, founders, investors, and industry leaders shaping the next generation of GI care. Scheduled for April 9–10, 2026 in Chicago, the summit will focus on the full innovation lifecycle—from early concept and validation to FDA strategy, reimbursement, and commercialization. Unlike traditional academic meetings, the Tech Summit is positioned as a hands-on forum for clinicians and entrepreneurs looking to translate ideas into real-world impact.
A recent feature in The Washington Post explores what could be the next frontier in obesity care: one-time gene therapies designed to replicate the metabolic effects of GLP-1 drugs without lifelong injections. While GLP-1 medications have driven unprecedented weight loss and market growth, a key limitation is durability—many patients discontinue treatment due to cost, side effects, or adherence challenges and subsequently regain weight. Researchers argue this drop-off undermines both clinical outcomes and long-term economic value. In response, several biotech efforts are pursuing gene therapies that permanently alter metabolic pathways, potentially delivering sustained appetite suppression or energy balance from a single…
A new scoping review covered by GI & Hepatology News highlights the growing potential of wearable technologies to transform how inflammatory bowel disease (IBD) is monitored and managed. Across 37 studies, researchers found that consumer wearables—such as smartwatches and fitness trackers—consistently captured meaningful changes in physical activity, sleep quality, heart rate, and heart rate variability that correlated with disease activity in Crohn’s disease and ulcerative colitis. In several longitudinal studies, physiologic changes appeared weeks before clinical flares, suggesting a role for earlier, more proactive intervention. Beyond consumer devices, early-stage biosensor patches showed promising correlations between sweat-based inflammatory markers (including CRP…
Obesity is on the rise in the United Status and across the globe, with recent reports estimating that nearly half of Americans will have obesity by 2030.1 This trend is thought to be due to multiple factors, including higher consumption of high-calorie, low-nutrient foods and decreased physical activity, as well as environmental and genetic factors. Although inflammatory bowel disease (IBD) is associated with chronic intestinal inflammation that portends malabsorption and nutritional deficiencies, which reduce body weight, the prevalence of obesity in patients with IBD is, in fact, rising in parallel to the rise in the general population. Large population-based studies…
As consolidation accelerates, many independent physicians are weighing whether to partner with a Management Services Organization (MSO), sell to private equity, merge with another practice, or join a hospital system. While these options are often discussed interchangeably, they differ significantly in structure, control, risk, and long-term implications. MSOs generally fall into two categories:
A new Medscape Medical News MedBrief reports that endoscopic ultrasound–guided choledochoduodenostomy (EUS-CDS) may offer a safer and more efficient alternative to ERCP in patients with malignant distal biliary obstruction. In comparative findings, EUS-CDS was associated with a lower rate of postprocedural pancreatitis, higher technical success, and shorter procedure times than ERCP. Post-ERCP pancreatitis remains the most common adverse event linked to the procedure, while EUS-CDS avoids manipulation of the papilla and pancreatic duct by creating a biliary bypass under ultrasound guidance.
Speaking at the Crohn’s & Colitis Congress, Frank I. Scott, MD, MSCE, cautioned that mentorship—while often career-accelerating—can become actively or passively harmful if toxic behaviors go unrecognized. Scott, an associate professor at University of Colorado Anschutz School of Medicine and codirector of the Crohn’s & Colitis Foundation’s IBD Qorus program, emphasized that strong mentorship is linked to higher publication rates, more protected time, better job satisfaction, and stronger career retention. But when mentorship fails, it can quietly derail academic progress. He outlined several mentorship archetypes, noting that effective mentoring often comes from a network—not a single individual—including traditional long-term mentors,…
MAGENTIQ EYE has released two upgraded versions of MAGENTIQ-COLO™, strengthening its AI-powered colonoscopy platform across both the U.S. and European markets. The FDA-cleared U.S. version introduces AI-based endoscopic tool detection, automatically pausing polyp detection overlays when tools enter the field of view—improving usability during intervention. The CE-marked European version goes further by adding computer-aided quality (CAQ) features, designed to support objective documentation of high-quality colonoscopy. New CE-marked capabilities include:
A new study published in The American Journal of Managed Care finds that an employer-sponsored digital digestive care management program significantly reduced healthcare spending for employees with chronic GI conditions. In a propensity-matched analysis, participants using virtual digestive care—combining symptom tracking, personalized nutrition therapy, health coaching, and education—had 18% lower total healthcare costs after one year compared with nonparticipants. This translated to $2,026 in annual savings per member. With an average program cost of $345 per member per year, the intervention generated a 5.87:1 return on investment, driven largely by reductions in inpatient admissions and emergency department visits, despite slightly…